John Borshoff – Managing Director – Deep Yellow (ASX:DYL) is successfully progressing a dual-pillar growth strategy to establish a globally diversified, Tier-1 uranium company to produce 10+ Mlb pa.
Copyright 2024 – Finance News Network
07 Jun 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's phase 1 trial results for its chlorotoxin CAR T (CLTX CAR T) cell therapy targeting glioblastoma.
25 Aug 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses reporting season and the lack of guidance from companies, cyclical businesses and M&A activity in the Energy sector.
20 Sep 2022 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari discusses the FDA's award of orphan status and rare paediatric disease designation for the company's DUNP19 technology.
11 Dec 2020 - Novatti Group Limited (ASX:NOV) Managing Director Peter Cook discusses the company's strategy of partnering with Tier 1 companies, including Ripple, Google Pay and Samsung Pay.
06 Apr 2021 - LaserBond Limited (ASX:LBL) CEO Wayne Hooper talks about the company's strong 1H21 results despite the impact of COVID-19, its focus on growth opportunities to expand its national footprint, and business strategy, including potential growth via acquisitions.
04 Mar 2024 - Andrew Radonjic - Managing Director - Venture Minerals (ASX:VMS) is dedicated to discovering and developing world-class mineral deposits to meet global demand for critical minerals vital to the green energy transition.
06 Sep 2024 - Bernie Fernandes, State Manager (WA & SA) of Sequoia Financial Group (ASX:SEQ), talks with CEO and Managing Director Garry Crole. Bernie shares insights for advisors from his long career.
31 Aug 2020 - Acorn Capital Resources and Energy Analyst Karina Bader talks about junior resource companies and how investors can try to make money as the companies move from explorers to developers to producers.
06 Nov 2019 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.